Microfluidic Droplet Sorting of MSCs for Therapeutic Cell Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for autoimmune diseases like rheumatoid arthritis have undesirable side effects and long-term resistance issues, necessitating an effective, economical, and side-effect-reduced alternative.
Innovation Solution
A method for producing mesenchymal stem cells (MSCs) involves culturing a heterogeneous population for 20-35 days, staining, droplet encapsulation, and size-based sorting using microfluidics to obtain viable MSCs expressing specific markers and genes, which are then used in compositions with excipients for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs (steroid hormones, biological agents, immunosuppressants) are used for treating autoimmune diseases, then therapeutic effect is achieved, but undesirable side effects occur (immune deficiency, gastrointestinal disorders, hormonal disturbances, cardiovascular complications)
Solution Approach 1:
The patent extracts and isolates specific mesenchymal stem cells from a heterogeneous population through microfluidic droplet encapsulation and size-based sorting. This extraction process separates the therapeutic cell subset (15-30 μm medium-sized MSCs) from non-therapeutic cells, achieving pure therapeutic cells without the harmful side effects associated with conventional drugs
Solution Approach 2:
The patent utilizes parameter changes in cell size (15-30 μm) as a selection criterion to identify and isolate therapeutically active MSCs. By changing the physical parameter of cell size and using it as a sorting criterion, the patent achieves selective isolation of cells with enhanced therapeutic potential and reduced side effects
2Duration of action of stationary object
If conventional treatments are administered long-term, then disease control is maintained, but resistance develops and economic burden increases
Solution Approach 1:
The patent employs self-service principles through autologous transplantation where patients receive their own mesenchymal stem cells that have been isolated, characterized, and expanded. This self-service approach eliminates resistance issues associated with long-term conventional drug treatment, as the cells are derived from the patient's own tissue and maintain long-term therapeutic efficacy without developing resistance
Solution Approach 2:
The patent performs preliminary actions by isolating and characterizing MSCs before transplantation, ensuring they meet specific criteria (size 15-30 μm, marker expression CD73, CD90, CD105). This preliminary selection and preparation ensures long-term therapeutic effectiveness and prevents resistance development during extended treatment periods
3Ease of manufacture
If heterogeneous MSC population is used for therapy, then treatment is simpler, but therapeutic efficacy is reduced due to presence of non-therapeutic cells
Solution Approach 1:
The patent applies segmentation by dividing the heterogeneous MSC population into distinct size-based subsets using microfluidic droplet encapsulation. This segmentation process separates medium-sized MSCs (15-30 μm) from small and large cells, creating a purified therapeutic population that maintains high efficacy while simplifying the manufacturing process through automated sorting
Solution Approach 2:
The patent replaces complex manual cell sorting methods with microfluidic automated sorting systems. This substitution uses physical principles (droplet generation, size-based separation) to automatically isolate medium-sized MSCs, achieving high purity therapeutic cells with simplified manufacturing compared to traditional manual techniques
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces viable MSCs with increased therapeutic potential, reducing side effects and overcoming resistance, suitable for treating autoimmune diseases and other conditions.
Implementation Method 1
adding droplet encapsulation media, comprising a density gradient solution to the heterogeneous population of stained MSCs, to obtain a population of microfluidic droplets
Data Source
AI summary
The present disclosure relates to a method for producing mesenchymal stem cells for therapeutic applications. The method comprises culturing of MSCs to obtain heterogeneous population. This heterogeneous population of MSCs were subjected to droplet encapsulation media to obtain a population of microfluidic droplets preferably comprising a single MSC; providing the population of microfluidic droplets to a microfluidics device; and identifying and selecting a homogeneous population of MSCs having medium size in the range of 15 to 30 μm showing high expression of cell surface markers (CD73, CD90) and increased expression of genes, such as COL12 A1; IGFBP5; THBS2; GREM1 and CDH2 genes. The MSCs having medium size are further cryopreserved to obtain a cell bank of MSCs with better stability and therapeutic potential in treating diseases like auto immune diseases.